Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | BC2059 |
Trade Name | |
Synonyms | BC-2059|BC 2059|Tegatrabetan|Tegavivint |
Drug Descriptions |
Tegavivint (BC2059) binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235, PMID: 30793158). |
DrugClasses | CTNNB1 Inhibitor 26 |
CAS Registry Number | 1227637-23-1 |
NCIT ID | C155885 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BC2059 | BC2059 | 0 | 1 |
BC2059 + Bortezomib | BC2059 Bortezomib | 0 | 0 |
BC2059 + Decitabine | BC2059 Decitabine | 0 | 1 |
BC2059 + Osimertinib | BC2059 Osimertinib | 0 | 1 |